These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38184429)

  • 21. Genotype, phenotype and treatment outcomes of 17 Malaysian patients with infantile-onset Pompe disease and the identification of 3 novel GAA variants.
    Chan MY; Jalil JA; Yakob Y; Wahab SAA; Ali EZ; Khalid MKNM; Leong HY; Chew HB; Sivabalakrishnan JB; Ngu LH
    Orphanet J Rare Dis; 2023 Aug; 18(1):231. PubMed ID: 37542277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Slow, progressive myopathy in neonatally treated patients with infantile-onset Pompe disease: a muscle magnetic resonance imaging study.
    Peng SS; Hwu WL; Lee NC; Tsai FJ; Tsai WH; Chien YH
    Orphanet J Rare Dis; 2016 May; 11(1):63. PubMed ID: 27183828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state.
    Matsuoka T; Miwa Y; Tajika M; Sawada M; Fujimaki K; Soga T; Tomita H; Uemura S; Nishino I; Fukuda T; Sugie H; Kosuga M; Okuyama T; Umeda Y
    Mol Genet Metab Rep; 2016 Dec; 9():98-105. PubMed ID: 27896132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
    Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pompe disease: early diagnosis and early treatment make a difference.
    Chien YH; Hwu WL; Lee NC
    Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal follow-up to evaluate speech disorders in early-treated patients with infantile-onset Pompe disease.
    Zeng YT; Hwu WL; Torng PC; Lee NC; Shieh JY; Lu L; Chien YH
    Eur J Paediatr Neurol; 2017 May; 21(3):485-493. PubMed ID: 28039015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene Therapy for Pompe Disease: The Time is now.
    Colella P; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease.
    De Groot AS; Desai AK; Lelias S; Miah SMS; Terry FE; Khan S; Li C; Yi JS; Ardito M; Martin WD; Kishnani PS
    Front Immunol; 2021; 12():636731. PubMed ID: 34220802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report.
    Rovelli V; Zuvadelli J; Piotto M; Scopari A; Dionigi AR; Ercoli V; Paci S; Cefalo G; Salvatici E; Banderali G
    Ital J Pediatr; 2022 Mar; 48(1):48. PubMed ID: 35346323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzyme replacement therapy for infantile-onset Pompe disease.
    Chen M; Zhang L; Quan S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011539. PubMed ID: 29155436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease.
    Kazi ZB; Desai AK; Troxler RB; Kronn D; Packman S; Sabbadini M; Rizzo WB; Scherer K; Abdul-Rahman O; Tanpaiboon P; Nampoothiri S; Gupta N; Feigenbaum A; Niyazov DM; Sherry L; Segel R; McVie-Wylie A; Sung C; Joseph AM; Richards S; Kishnani PS
    Genet Med; 2019 Apr; 21(4):887-895. PubMed ID: 30214072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. When should we start enzyme replacement therapy for infantile Pompe disease with severe cardiomyopathy?
    Bonilla-Palomas JL; Gámez-López AL; Tejero-Hernández MA; Tejero-Mateo I; López-López J
    Rev Esp Cardiol (Engl Ed); 2012 Jan; 65(1):100-2. PubMed ID: 21715078
    [No Abstract]   [Full Text] [Related]  

  • 33. Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation.
    Desai AK; Walters CK; Cope HL; Kazi ZB; DeArmey SM; Kishnani PS
    Mol Genet Metab; 2018 Feb; 123(2):92-96. PubMed ID: 29289479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment.
    Yang CF; Liu HC; Hsu TR; Tsai FC; Chiang SF; Chiang CC; Ho HC; Lai CJ; Yang TF; Chuang SY; Lin CY; Niu DM
    Am J Med Genet A; 2014 Jan; 164A(1):54-61. PubMed ID: 24243590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Outcome of Infantile Onset Pompe Disease Patients Treated with Enzyme Replacement Therapy - Data from a German-Austrian Cohort.
    Pfrimmer C; Smitka M; Muschol N; Husain RA; Huemer M; Hennermann JB; Schuler R; Hahn A
    J Neuromuscul Dis; 2024; 11(1):167-177. PubMed ID: 38043017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ocular and histologic findings in a series of children with infantile pompe disease treated with enzyme replacement therapy.
    Prakalapakorn SG; Proia AD; Yanovitch TL; DeArmey S; Mendelsohn NJ; Aleck KA; Kishnani PS
    J Pediatr Ophthalmol Strabismus; 2014; 51(6):355-62. PubMed ID: 25139343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRIM-negative infantile Pompe disease: 42-month treatment outcome.
    Rohrbach M; Klein A; Köhli-Wiesner A; Veraguth D; Scheer I; Balmer C; Lauener R; Baumgartner MR
    J Inherit Metab Dis; 2010 Dec; 33(6):751-7. PubMed ID: 20882352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcomes of very early treated infantile-onset Pompe disease with short-term steroid premedication: experiences from a nationwide newborn screening programme.
    Yang CF; Liao TE; Chu YL; Chen LZ; Huang LY; Yang TF; Ho HC; Kao SM; Niu DM
    J Med Genet; 2023 May; 60(5):430-439. PubMed ID: 36137614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry.
    Martinez-Marin RJ; Reyes-Leiva D; Nascimento A; Muelas N; Dominguez-González C; Paradas C; Olivé M; García-Romero M; Pascual-Pascual SI; Grau JM; Barba-Romero MA; Gomez-Caravaca MT; de Las Heras J; Casquero P; Mendoza MD; de León JC; Gutierrez A; Morís G; Blanco-Lago R; Ramos-Fransi A; Pintós G; García-Antelo MJ; Rabasa M; Morgado Y; Usón M; Miralles FJ; Bárcena-Llona JE; Gómez-Belda AB; Pedraza-Hueso MI; Hortelano M; Colomé A; Garcia-Martin G; Lopez de Munain A; Jericó I; Galán-Dávila L; Pardo J; Salgueiro-Origlia G; Alonso-Pérez J; Pla-Junca F; Schiava M; Segovia-Simón S; Díaz-Manera J
    Neuromuscul Disord; 2024 Jan; 34():1-8. PubMed ID: 38087756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Very Early Treatment for Infantile-Onset Pompe Disease Contributes to Better Outcomes.
    Yang CF; Yang CC; Liao HC; Huang LY; Chiang CC; Ho HC; Lai CJ; Chu TH; Yang TF; Hsu TR; Soong WJ; Niu DM
    J Pediatr; 2016 Feb; 169():174-80.e1. PubMed ID: 26685070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.